russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2018-3-76-81russjcardiol-2754Research ArticleСОВЕТ ЭКСПЕРТОВEXPERT CONSENSUSЗАКЛЮЧЕНИЕ РАБОЧЕЙ ГРУППЫ ПО АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ. МЕСТО САРТАНОВ В ТЕРАПИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ В XXI ВЕКЕARTERIAL HYPERTENSION WORKGROUP RESOLUTION. THE ROLE OF SARTANS IN TREATMENT OF SYSTEMIC HYPERTENSION IN THE 21ST CENTURYКонрадиА. О.KonradiA. O.

Конради А. О. — член-корреспондент РАН, доктор медицинских наук, профессор, зам. генерального директора по научной работе, зав. научно-исследовательским отделом артериальной гипертензии.

Saint-Petersburg.

ЖдановаО. Н.ZhdanovaO. N.

 Жданова О. Н. — кандидат медицинских наук, доцент кафедры факультетской терапии с курсом эндокринологии.

Санкт-Петербург.

Saint-Petersburg.

РотарьО. П.RotarO. P.

 Ротарь О. П. — доктор медицинских наук, зав. НИЛ эпидемиологии неинфекционных заболеваний.

Санкт-Петербург.

Saint-Petersburg.

КарповЮ. А.KarpovYu. A.

Карпов Ю. А. — профессор, доктор медицинских наук, руководитель отдела ангиологии института клинической кардиологии.

Москва.

Moscow.

ПодзолковВ. И.PodzolkovV. I.

Подзолков В. И. — профессор, доктор медицинских наук, зав. кафедрой факультетской терапии № 2.

Москва. 

Moscow.

ЛебедевП. А.LebedevP. A.

Лебедев П. А. — доктор медицинских наук, профессор, главный внештатный специалист Минздрава Самарской области по функциональной диагностике, зав. кафедрой терапии ИПО.

Самара.

Samara.

ЧесниковаА. И.ChesnikovaA. I.

Чесникова А. И. — доктор медицинских наук, профессор кафедры внутренних болезней № 1.

Ростов-на-Дону.

Rostov-na-Donu.

НебиеридзеД. В.NebieridzeD. V.

Небиеридзе Д. В. — профессор, доктор медицинских наук, руководитель отдела профилактики метаболических нарушений.

Москва.

Moscow.

МиллерО. Н.MillerO. N.

Миллер О. Н. — доктор медицинских наук, профессор кафедры неотложной терапии с эндокринологией и профпатологией факультета повышения квалификации и профессиональной переподготовки врачей.

Новосибирск.

Novosibirsk.

СоловьеваЕ. В.SolovjovaE. V.

Соловьева Е. В. — кандидат медицинских наук, доцент кафедры терапии.

Нижний Новгород.

Nizhny Novgorod.

КуликовА. Н.KulikovA. N.

Куликов А. Н. — доктор медицинских наук, профессор, врач-кардиолог высшей категории, зам. начальника кафедры пропедевтики внутренних болезней.

Санкт-Петербург

Saint-Petersburg.

Национальный медицинский исследовательский центр им. В. А. Алмазова.РоссияFederal Almazov North-West Medical Research Center of the Ministry of Health.Russian FederationСанкт-Петербургский государственный медицинский университет имени акад. И. П. Павлова.РоссияPavlov First Saint Petersburg State Medical University.Russian FederationФГБУ НМИЦ клинической кардиологии им. А. Л. Мясникова Минздрава России.РоссияMyasnikov Scientific Medical Research Center of Clinical Cardiology of the Ministry of Health.Russian FederationСеченовский Университет.РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Health.Russian FederationИнститут Профессионального образования СамГМУ.Россия5Institute for Professional Education of SamSMU.Russian FederationРостовский государственный медицинский университет.РоссияRostov State Medical University.Russian FederationГНИЦ профилактической медицины Минздрава России.РоссияNational Research Center for Preventive Medicine of the Ministry of Health.Russian FederationНовосибирский Государственный Медицинский Университет.РоссияNovosibirsk State Medical University.Russian FederationНижегородская государственная медицинская академия Минздрава России.РоссияNizhny Novgorod State Medical Academy of the Ministry of Health.Russian FederationВоенно-Медицинская академия им. Кирова.РоссияKirov Military Medical Academy.Russian Federation201810042018037681Copyright © Конради А.О., Жданова О.Н., Ротарь О.П., Карпов Ю.А., Подзолков В.И., Лебедев П.А., Чесникова А.И., Небиеридзе Д.В., Миллер О.Н., Соловьева Е.В., Куликов А.Н., 20182018Конради А.О., Жданова О.Н., Ротарь О.П., Карпов Ю.А., Подзолков В.И., Лебедев П.А., Чесникова А.И., Небиеридзе Д.В., Миллер О.Н., Соловьева Е.В., Куликов А.Н.Konradi A.O., Zhdanova O.N., Rotar O.P., Karpov Y.A., Podzolkov V.I., Lebedev P.A., Chesnikova A.I., Nebieridze D.V., Miller O.N., Solovjova E.V., Kulikov A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2754

.

.

ReferencesWorld Health organization. The top 10 causes of death. http://www.who.int/mediacentre/ factsheets/fs310/en/ (January 2017) дата последнего доступа 12.01.2018.World Health organization. The top 10 causes of death. http://www.who.int/mediacentre/ factsheets/fs310/en/ (January 2017) дата последнего доступа 12.01.2018.Данные Росстат, www.gks.ru дата последнего доступа 12.01.2018.Данные Росстат, www.gks.ru дата последнего доступа 12.01.2018.Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002 Nov 2; 360 (9343): 1347-60.Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002 Nov 2; 360 (9343): 1347-60.Diagnostics and treatment of arterial hypertension. Kardiologicheskij Vestnik; 2015 (1): 3-30. (In Russ.) Диагностика и лечение артериальной гипертонии. Кардиологический вестник, 2015 (1): 3-30.Diagnostics and treatment of arterial hypertension. Kardiologicheskij Vestnik; 2015 (1): 3-30. (In Russ.) Диагностика и лечение артериальной гипертонии. Кардиологический вестник, 2015 (1): 3-30.2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34: 2159-219.2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34: 2159-219.Boytsov SA, et al. Arterial hypertension among individuals pf 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014; 13 (4): 4-14. (In Russ.) Бойцов С. А. и соавт. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика 2014; 13 (4): 4-14. DOI: 10.15829/1728-8800-2014-4-4-14.Boytsov SA, et al. Arterial hypertension among individuals pf 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014; 13 (4): 4-14. (In Russ.) Бойцов С. А. и соавт. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика 2014; 13 (4): 4-14. DOI: 10.15829/1728-8800-2014-4-4-14.Mancia G, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul; 31 (7): 1281-357.Mancia G, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul; 31 (7): 1281-357.Dzau VJ, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006 Dec 19; 114 (25): 2850-70. Schrader J, et al. MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005 Jun; 36 (6): 1218-26. Haller H, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. March 10, 2011 N Engl J Med 2011; 364: 907-17. Parving, et al. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2. September 20, 2001 N Engl J Med 2001; 345: 870-8. Lewis EJ, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 851-60. Carson P, et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005; 11: 576-85. Papademetriou V, et al. Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004 Sep 15; 44 (6): 1175-80. Pfeffer MA, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6; 362 (9386): 759-66. Erratum in: Lancet. 2009 Nov 21-2009 Nov 27; (9703): 1744. Brenner, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med. 2001; 345: 861-9. Pitt B, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial — the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000 May 6; 355 (9215): 1582-7. Dickstein K, et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 75260. Dahlöf B. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23; 359 (9311): 995-1003. Cohn JN. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 6; 345 (23): 1667-75. NAVIGATOR study group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010; 362: 1477-90. Pfeffer M. A. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13; 349 (20): 1893-906. Julius S, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19; 363 (9426): 2022-31. Mann JF, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 Aug 16; 372 (9638): 547-53.Dzau VJ, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006 Dec 19; 114 (25): 2850-70. Schrader J, et al. MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005 Jun; 36 (6): 1218-26. Haller H, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. March 10, 2011 N Engl J Med 2011; 364: 907-17. Parving, et al. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2. September 20, 2001 N Engl J Med 2001; 345: 870-8. Lewis EJ, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 851-60. Carson P, et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005; 11: 576-85. Papademetriou V, et al. Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004 Sep 15; 44 (6): 1175-80. Pfeffer MA, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6; 362 (9386): 759-66. Erratum in: Lancet. 2009 Nov 21-2009 Nov 27; (9703): 1744. Brenner, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med. 2001; 345: 861-9. Pitt B, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial — the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000 May 6; 355 (9215): 1582-7. Dickstein K, et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 75260. Dahlöf B. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23; 359 (9311): 995-1003. Cohn JN. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 6; 345 (23): 1667-75. NAVIGATOR study group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010; 362: 1477-90. Pfeffer M. A. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13; 349 (20): 1893-906. Julius S, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19; 363 (9426): 2022-31. Mann JF, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 Aug 16; 372 (9638): 547-53.Law M, et al. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technology Assessment 2003; 7 (31).Law M, et al. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technology Assessment 2003; 7 (31).Conlin PR, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.Conlin PR, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.Ruilope LM. Telmisartan for the management of patients at high cardiovascular risk. Journal Current Medical Research and Opinion. 2011, 27 (8): 1673-82.Ruilope LM. Telmisartan for the management of patients at high cardiovascular risk. Journal Current Medical Research and Opinion. 2011, 27 (8): 1673-82.Manfredini R, et al. Circadian Variation in Stroke Onset: Identical Temporal Pattern in Ischemic and Hemorrhagic Events. Chronobiology International. 2005; 22 (3); 417-53.Manfredini R, et al. Circadian Variation in Stroke Onset: Identical Temporal Pattern in Ischemic and Hemorrhagic Events. Chronobiology International. 2005; 22 (3); 417-53.Инструкция по медицинскому применению лекарственного препарата Телзап — ЛП-003545, 09.08.2017.Инструкция по медицинскому применению лекарственного препарата Телзап — ЛП-003545, 09.08.2017.Инструкции по медицинскому применению лекарственных препаратов Апровель — ЛП-001260, 23.11.2016, Кардосал 20 — ЛСР-000628/10, 06.02.2017, Эдарби — ЛП-002359, 11.07.2016, Атаканд — П N014373/01, 25.12.2015, Теветен — П N012018/01, 20.04.2016, Диован — ЛП-002136, 12.04.2016.Инструкции по медицинскому применению лекарственных препаратов Апровель — ЛП-001260, 23.11.2016, Кардосал 20 — ЛСР-000628/10, 06.02.2017, Эдарби — ЛП-002359, 11.07.2016, Атаканд — П N014373/01, 25.12.2015, Теветен — П N012018/01, 20.04.2016, Диован — ЛП-002136, 12.04.2016.White WB, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-53.White WB, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-53.ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10; 358 (15): 1547-59.ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10; 358 (15): 1547-59.The Telmisartan Randomised Assessment Study in ACE in tolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Lancet 2008; 372: 1174-83.The Telmisartan Randomised Assessment Study in ACE in tolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Lancet 2008; 372: 1174-83.Chazova IE. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. System Hypertension 2010; 3: 5-26. (In Russ.) И. Е. Чазова и соавт. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5-26.Chazova IE. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. System Hypertension 2010; 3: 5-26. (In Russ.) И. Е. Чазова и соавт. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5-26.Lacourciere, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus HCTZ in patients uncontrolled with telmisartan monotherapy. Journal of Human Hypertension, 2001, (15): 763-70.Lacourciere, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus HCTZ in patients uncontrolled with telmisartan monotherapy. Journal of Human Hypertension, 2001, (15): 763-70.Инструкции по применению лекарственных препаратов для медицинского применения: Лозап® Плюс ЛСР-000084, 04.09.2014, Телзап® Плюс ЛП-004359, 27.11.2017, Коапровель® ЛП-001027, 08.11.2016, Кардосал® Плюс ЛСР-007457/10, 04.10.2013, Атаканд® Плюс ЛСР-001340/08, 25.10.2017, Теветен® Плюс ЛС-000319, 27.04.2016, Ко-Диован® ЛП-000689, 07.05.2015.Инструкции по применению лекарственных препаратов для медицинского применения: Лозап® Плюс ЛСР-000084, 04.09.2014, Телзап® Плюс ЛП-004359, 27.11.2017, Коапровель® ЛП-001027, 08.11.2016, Кардосал® Плюс ЛСР-007457/10, 04.10.2013, Атаканд® Плюс ЛСР-001340/08, 25.10.2017, Теветен® Плюс ЛС-000319, 27.04.2016, Ко-Диован® ЛП-000689, 07.05.2015.Sharma AM, et al. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. 2007; 6: 28.Sharma AM, et al. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. 2007; 6: 28.Schumacher H, et al. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl. 2008 Jun; 1: 32-40.Schumacher H, et al. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl. 2008 Jun; 1: 32-40.Musini V, et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014 May 29 (5): CD003824.Musini V, et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014 May 29 (5): CD003824.Kobalava ZD. Is uric acid a marker and/or a new risk factor for cardiovascular complications? Clinical pharmacology and therapy. 2002 (11) 3: 32-9. (In Russ.) Кобалава Ж. Д. Мочевая кислота — маркер и/или новый фактор риска сердечно-сосудистых осложнений? Клиническая фармакология и терапия. 2002; (11) 3: 32-9.Kobalava ZD. Is uric acid a marker and/or a new risk factor for cardiovascular complications? Clinical pharmacology and therapy. 2002 (11) 3: 32-9. (In Russ.) Кобалава Ж. Д. Мочевая кислота — маркер и/или новый фактор риска сердечно-сосудистых осложнений? Клиническая фармакология и терапия. 2002; (11) 3: 32-9.Chazova IE, et al. Recommendations for management of patients with arterial hypertension with metabolic disorders. Cardiologicheskij Vestnik 2014; XIX (XXI): 1: 4-57. (In Russ.) Чазова И. Е. и соавт. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический вестник 2014; XIX (XXI): 1: 4-57.Chazova IE, et al. Recommendations for management of patients with arterial hypertension with metabolic disorders. Cardiologicheskij Vestnik 2014; XIX (XXI): 1: 4-57. (In Russ.) Чазова И. Е. и соавт. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический вестник 2014; XIX (XXI): 1: 4-57.Mamedov MN, et al. Metabolic syndrome — more than a combination of risk factors: the principles of diagnosis and treatment. Manuals for doctors, 2006, 48 p. (In Russ.) Мамедов М. Н. Метаболический синдром — больше чем сочетание факторов риска: принципы диагностики и лечения. Пособие для врачей, 2006, с. 48.Mamedov MN, et al. Metabolic syndrome — more than a combination of risk factors: the principles of diagnosis and treatment. Manuals for doctors, 2006, 48 p. (In Russ.) Мамедов М. Н. Метаболический синдром — больше чем сочетание факторов риска: принципы диагностики и лечения. Пособие для врачей, 2006, с. 48.Инструкция по медицинскому применению лекарственного препарата Лозап АМ — ЛП-001481, 03.04.2017.Инструкция по медицинскому применению лекарственного препарата Лозап АМ — ЛП-001481, 03.04.2017.Kim HK, et al. Patent: (s)-(-)-amlodipine camsylate or a hydrate thereof and a pharmaceutical composition compirising them. http://www.findpatent.ru/patent/240/2403241.html.Kim HK, et al. Patent: (s)-(-)-amlodipine camsylate or a hydrate thereof and a pharmaceutical composition compirising them. http://www.findpatent.ru/patent/240/2403241.html.Moon JH, et al. Patent: Amlodipine camsylate, a process for its preparation and a pharmaceutical composition based on it. http://www.freepatent.ru/patents/2241701.Moon JH, et al. Patent: Amlodipine camsylate, a process for its preparation and a pharmaceutical composition based on it. http://www.freepatent.ru/patents/2241701.Kohlmann OJr, et al. The LOTHAR study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq. Bras. Cardiol. 2006 Jan; 86 (1): 39-51.Kohlmann OJr, et al. The LOTHAR study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq. Bras. Cardiol. 2006 Jan; 86 (1): 39-51.Nidhi S, et al. The effects of Amlodipine plus Losartan combination versus Amlodipine alone on serum uric acid levels in hypertension at a tertiary care hospital of north India. World Journal of Pharmaceuticals Science. 2016; 4 (11): 195-9.Nidhi S, et al. The effects of Amlodipine plus Losartan combination versus Amlodipine alone on serum uric acid levels in hypertension at a tertiary care hospital of north India. World Journal of Pharmaceuticals Science. 2016; 4 (11): 195-9.Nishida, et al. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Cardiovascular Diabetology 2013, 12: 159.Nishida, et al. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Cardiovascular Diabetology 2013, 12: 159.Hamada T, et al. Uricosuric Action of Losartan via the Inhibition of Urate Transporter 1 (URAT 1) in Hypertensive Patients. Am J Hypertens, 2008; 21 (10): 1157-62.Hamada T, et al. Uricosuric Action of Losartan via the Inhibition of Urate Transporter 1 (URAT 1) in Hypertensive Patients. Am J Hypertens, 2008; 21 (10): 1157-62.Konradi AO, et al. Insufficiency adherence to the treatment of hypertension: the causes and ways of correction. Arterial hypertension 2004; 10, 3: 137-43. (In Russ.) Конради А. О. и др. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Consilium Medicum. 2004; 10, 3: 137-43.Konradi AO, et al. Insufficiency adherence to the treatment of hypertension: the causes and ways of correction. Arterial hypertension 2004; 10, 3: 137-43. (In Russ.) Конради А. О. и др. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Consilium Medicum. 2004; 10, 3: 137-43.Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich). 2006 Jan; 8 (1): 53-6. Review.Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich). 2006 Jan; 8 (1): 53-6. Review.Makani H, et al. Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema. The American Journal of Medicine (2011) 124: 128-35.Makani H, et al. Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema. The American Journal of Medicine (2011) 124: 128-35.Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002; (13) 5: 1338-49.Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002; (13) 5: 1338-49.Kobalava ZD, et al. National recommendations: Cardiovascular risk and chronic kidney disease: strategies for cardio-nephroprotection. Clinical pharmacology and therapy, 2014; 23 (3): 4-27. (In Russ.) Кобалава Ж. Д. и др. Национальные рекомендации: Сердечнососудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клиническая фармакология и терапия. 2014; 23 (3): 4-27.Kobalava ZD, et al. National recommendations: Cardiovascular risk and chronic kidney disease: strategies for cardio-nephroprotection. Clinical pharmacology and therapy, 2014; 23 (3): 4-27. (In Russ.) Кобалава Ж. Д. и др. Национальные рекомендации: Сердечнососудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клиническая фармакология и терапия. 2014; 23 (3): 4-27.Kobalava ZD, et al. Prevalence of markers of chronic kidney disease in patients with arterial hypertension: the results of an epidemiological study CHRONOGRAPH. Cardiology 2017, 57 (10): 39-44. (In Russ.) Кобалава Ж. Д. и др. от имени исследователей программы ХРОНОГРАФ. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией: результаты эпидемиологического исследования ХРОНОГРАФ. Кардиология. 2017; 57 (10): 39-44.Kobalava ZD, et al. Prevalence of markers of chronic kidney disease in patients with arterial hypertension: the results of an epidemiological study CHRONOGRAPH. Cardiology 2017, 57 (10): 39-44. (In Russ.) Кобалава Ж. Д. и др. от имени исследователей программы ХРОНОГРАФ. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией: результаты эпидемиологического исследования ХРОНОГРАФ. Кардиология. 2017; 57 (10): 39-44.Roscioni SS, et al. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol. 2014; 10: 77-87.Roscioni SS, et al. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol. 2014; 10: 77-87.Parving HH, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870-8.Parving HH, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870-8.Lewis EJ, et al. Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 851-60.Lewis EJ, et al. Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 851-60.Bobrie G. Investigators ICS. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. Clin Ther 2012; 34: 1705-19. Bobrie G. Investigators IAS. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. Clin Ther 2012; 34: 1720-34.e1723.Bobrie G. Investigators ICS. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. Clin Ther 2012; 34: 1705-19. Bobrie G. Investigators IAS. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. Clin Ther 2012; 34: 1720-34.e1723.Kobalava ZD. Fixed combination irbesartan/amlodipine: efficacy and safety of 4 dose regimens in patients with arterial hypertension. Cardiology 2014; 6: 15-20. (In Russ.) Кобалава Ж. Д. Фиксированная комбинация ирбесартан/амлодипин: эффективность и безопасность применения 4 дозовых режимов у пациентов с артериальной гипертонией. Кардиология. 2014; 6: 15-20.Kobalava ZD. Fixed combination irbesartan/amlodipine: efficacy and safety of 4 dose regimens in patients with arterial hypertension. Cardiology 2014; 6: 15-20. (In Russ.) Кобалава Ж. Д. Фиксированная комбинация ирбесартан/амлодипин: эффективность и безопасность применения 4 дозовых режимов у пациентов с артериальной гипертонией. Кардиология. 2014; 6: 15-20.Инструкция по медицинскому применению лекарственного препарата Апровель — ЛП-001260, 23.11.2016.Инструкция по медицинскому применению лекарственного препарата Апровель — ЛП-001260, 23.11.2016.

The authors declare that there are no conflicts of interest present.